With the revision of guidelines for treating hyperlipidemia in Korea announced, attention is focused on how it will affect the prescription performance of major drugs. The pharmaceutical industry predicts that the Atorvastatin and Ezetimibe market, which has recently been growing rapidly, will benefit the most from the revision of the guidelines.

Domestic pharmaceutical companies that have recently entered this market are also in the midst of preparing marketing and sales strategies with guidelines in mind.

◆ Proactive treatment for patients with high-risk hyperlipidemia

According to the pharmaceutical industry on the 9th, The Korean Society of Lipid and Atherosclero